{
    "title": "111_hr1032",
    "content": "The Act may be cited as the \"Heart Disease Education, Analysis Research, and Treatment for Women Act\" or the \"HEART for Women Act\". The Government Accountability Office is required to submit a report. The Comptroller General of the United States will conduct a study on sponsors' compliance with FDA requirements for clinical studies of drugs, biologics, and devices. A report will be submitted to relevant committees within 12 months of the Act's enactment. The report will include a description of FDA assistance to sponsors, the effectiveness of FDA enforcement, and an analysis of representation of females, minorities, and adults in clinical studies for evaluating product safety and effectiveness. The report will evaluate product safety and effectiveness data availability by gender, age, and racial subgroup. Recommendations for modifications to requirements and FDA oversight will be made. The Secretary of Health and Human Services will submit the report within 6 months of the Comptroller General's report. The Secretary of Health and Human Services will submit a response to the report on product safety and effectiveness data availability, including a corrective action plan if needed. Definitions for \"biologic,\" \"device,\" and \"drug\" are provided in this section. SEC. 3. REPORTING ON QUALITY OF AND ACCESS TO CARE FOR WOMEN WITH CARDIOVASCULAR DISEASES. The Secretary of Health and Human Services is required to submit an annual report to Congress on the quality of and access to care for women with heart disease, stroke, and other cardiovascular diseases, with recommendations for improving treatment and eliminating disparities. The Wisewoman Program under the Public Health Service Act is extended with increased funding authorized for fiscal years 2012 to 2016. The Wisewoman Program under the Public Health Service Act is extended with increased funding authorized for fiscal years 2012 to 2016. Passed the House of Representatives on September 30, 2010."
}